InvestSMART

Avecho Biotechnology Limited (ASX: AVE) - Announcements

- Current share price for AVE : $0.021

ASX company news and announcements for Avecho Biotechnology Limited (AVE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Avecho Biotechnology Limited (AVE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Avecho Biotechnology Limited (AVE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Avecho Biotechnology Limited (AVE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$81 Application for quotation of securities - AVE 10 May 2023 9:06AM $0.005 $0.021 risen by 366.67%
$81 Results of Entitlement Offer 9 May 2023 8:39AM $0.006 $0.021 risen by 281.82%
$81 Receipt of R&D Tax Incentive 2 May 2023 12:38PM $0.006 $0.021 risen by 250%
$81 March 2023 Quarterly Activities Report & Appendix 4C 28 Apr 2023 9:20AM $0.005 $0.021 risen by 320%
$81 Notice of Annual General Meeting/Proxy Form 21 Apr 2023 8:38AM $0.005 $0.021 risen by 320%
$81 Notice to Ineligible Foreign Shareholders 13 Apr 2023 8:39AM $0.005 $0.021 risen by 320%
$81 Notice to Eligible Shareholders 13 Apr 2023 8:36AM $0.005 $0.021 risen by 320%
$81 Letter to Optionholders 3 Apr 2023 10:32AM $0.007 $0.021 risen by 223.08%
$81 Target Market Determination 3 Apr 2023 10:27AM $0.007 $0.021 risen by 223.08%
$81 Proposed issue of securities - AVE 3 Apr 2023 10:25AM $0.007 $0.021 risen by 223.08%
$81 Investor Presentation 3 Apr 2023 10:24AM $0.007 $0.021 risen by 223.08%
$81 Prospectus 3 Apr 2023 9:42AM $0.009 $0.021 risen by 133.33%
$81 Entitlement Offer to raise $11m for Phase 3 clinical trial 3 Apr 2023 9:40AM $0.009 $0.021 risen by 133.33%
$81 Avecho to present at NWR Virtual Healthcare Conference 17 Mar 2023 9:35AM $0.009 $0.021 risen by 133.33%
$81 Appendix 4G and Corporate Governance Statement 15 Mar 2023 5:31PM $0.008 $0.021 risen by 162.50%
$81 Annual Report - 31 December 2022 15 Mar 2023 5:28PM $0.008 $0.021 risen by 162.50%
$81 Appendix 4E - Preliminary Final Report 28 Feb 2023 9:17AM $0.009 $0.021 risen by 133.33%
$81 Clinical CBD program expands with the Lambert Initiative 22 Feb 2023 8:25AM $0.009 $0.021 risen by 133.33%
$81 December 2022 Quarterly Activities Report & Appendix 4C 31 Jan 2023 8:36AM $0.014 $0.021 risen by 50%
$81 Athenex submits Avecho's phytonadione to FDA pre-IND 12 Jan 2023 11:49AM $0.013 $0.021 risen by 61.54%
$81 Avecho receives ethics approval for Phase III CBD trial 22 Dec 2022 9:52AM $0.011 $0.021 risen by 90.91%
$81 AVE signs development agreement with Perrigo 20 Dec 2022 8:52AM $0.010 $0.021 risen by 110%
$81 September 2022 Quarterly Activities Report & Appendix 4C 28 Oct 2022 8:36AM $0.009 $0.021 risen by 133.33%
$81 Increased CBD absorption in dogs vs commercial comparator 19 Sep 2022 10:02AM $0.011 $0.021 risen by 90.91%
$81 Application for quotation of securities - AVE 1 Sep 2022 9:10AM $0.012 $0.021 risen by 75%

126 - 150 of 316 results

Page 6 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.